Amzell, B.V., in Collaboration with Amring Pharmaceuticals Inc. Announce Their Lead Product has Entered Phase III Clinical Trial in the U.S. for Treatment of Infantile Epileptic Disease

November 22, 2021

Amzell, B.V., a specialty pharmaceutical development company based in The Netherlands, and Amring Pharmaceuticals Inc. (Amring), a niche brand and generic pharmaceutical company based in Berwyn, PA, announced today that their lead product in the collaboration, AMZ002, has entered Phase III Clinical Trial in the U.S. for treatment of infantile epileptic disease.

Read more